|1.||Stieber, Petra: 7 articles (10/2014 - 01/2006)|
|2.||Nagel, Dorothea: 7 articles (10/2014 - 01/2006)|
|3.||Schneider, Joachim: 7 articles (01/2010 - 06/2002)|
|4.||Holdenrieder, Stefan: 6 articles (04/2015 - 01/2006)|
|5.||Filella, Xavier: 6 articles (10/2011 - 01/2005)|
|6.||Peretz, Tamar: 4 articles (10/2015 - 06/2002)|
|7.||Barak, Vivian: 4 articles (10/2015 - 06/2002)|
|8.||Chung, Kyung Young: 4 articles (06/2013 - 08/2011)|
|9.||Molina, Rafael: 4 articles (01/2009 - 05/2005)|
|10.||Ohtsuki, Y: 4 articles (04/2004 - 10/2000)|
03/01/1999 - "Cyfra 21-1 levels in SCC patients were significantly greater than those of healthy patients by 73% (P < or = 0.0001), patients with benign tumors by 74% (P < or = 0.0003), and patients in disease remission by 66% (P < or = 0.0002). "
11/01/2014 - "This study demonstrates the existence of a significant relationship between total tumor burden and the serum Cyfra 21.1 level in NSCLC patients who had not received treatment. "
01/01/2003 - "The concentrations of Cyfra 21.1, SCC and TPS has been analysed in several groups of head and neck tumors, but exclusively in larynx there are no studies concerning this subject. "
08/01/2002 - "In the present study, we hypothesized that released CYFRA 21-1 is closely associated with cellular apoptosis during tumor growth. "
12/01/2000 - "This study examines a new tumour marker, Cyfra 21-1, as a prognostic marker in predicting the survival of H&N cancer patients, and its correlation with clinical outcome during prolonged follow up of these patients. "
|2.||Lung Neoplasms (Lung Cancer)
01/01/2002 - "CYFRA 21-1 and NSE may help to differentiate cell types in lung cancer patients. "
11/09/2012 - "A total of 22 studies were available for analysis, and the high CYFRA 21-1 level in MPE was significantly associated with risk for lung cancer (standardized mean difference [SMD] = 1.65, 95% confidence interval [CI] = 1.48-1.82, Z = 18.97, p < 0.00001) compared with BPE. "
12/01/1998 - "In the current study, the prognostic information provided by the CYFRA 21-1 assay in operable nonsmall cell lung cancer (NSCLC) was analysed. "
03/01/1997 - "The diagnostic value of Cyfra 21-1 in non-small lung cancer (NSCLC) has been established, but few studies have focused on its prognostic value. "
01/01/1997 - "The present study suggests that CYFRA 21-1 might be useful as a possible indicator of survival and therapeutic effect for lung cancer."
|3.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/01/2003 - "Serum SCC, CYFRA 21-1, and CEA are the common tumour markers for head and neck squamous cell carcinoma (HNSCC), although diagnostic sensitivity should be yet improved, especially at early stages. "
01/01/2015 - "This study was designed to estimate the levels of salivary and serum CYFRA 21-1 in patients with oral precancer and oral squamous cell carcinoma (OSCC) and compare them with healthy controls. "
09/01/2013 - "After a systematic literature review and selection of English language studies, sensitivity, specificity and other measures of accuracy of Cyfra 21-1 in the diagnosis of head and neck squamous cell carcinoma were pooled using random effects models. "
03/01/1995 - "We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of serum SCC and serum CYFRA 21-1 for the whole study group and separately for the keratinizing and nonkeratinizing squamous-cell carcinoma group. "
02/01/1995 - "Cyfra 21-1 evaluation in head and neck squamous cell carcinoma is worthwhile for performance of an ample study that will prove and establish its routine use."
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/01/2012 - "CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304."
10/01/2011 - "This study investigated the preoperative serum levels of CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. "
07/01/1999 - "The aim of this study was to evaluate the prognostic significance of preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels in 62 patients submitted to radical surgery for non-small cell lung cancer (NSCLC). "
10/01/1995 - "The aim of this study was to evaluate serial determinations of CYFRA 21-1 in the follow-up of patients treated surgically for non-small cell lung cancer in order to predict the risk of tumour recurrence. "
07/01/1995 - "The aims of this study were (1) to confirm sensitivity and specificity of Cyfra 21-1 in detecting non-small cell lung cancer (NSCLC) and especially the squamous cell subtype, (2) to assess the potential relationship between Cyfra 21-1 and disease stage of the disease in NSCLC, and (3) to evaluate prognostic effect of Cyfra 21-1 in NSCLC. "
05/01/2007 - "In our experience the low sensitivity of urinary CYFRA 21.1, even using lower cutoff values and/or a combination with cytology and/or haemoglobin dipstick, makes its application not very useful as a surveillance tool for superficial bladder carcinoma."
01/01/2008 - "Additionally, a role of Cyfra 21.1 as a dedifferentiation marker in patients with classical differentiated thyroid carcinomas may be postulated and should be explored by further focused studies."
08/01/2004 - "[CEA and Cyfra 21.1 study pre-treatment in 252 patients with head and neck carcinomas]."
01/01/2001 - "A prospective clinical study was conducted to investigate the value of Cyfra 21-1 for diagnosis, determination of subtypes, staging, and evaluation of therapy response in patients with lung carcinoma (Ca). "
11/01/2000 - "This study was conducted to determine a potential use of CYFRA 21-1 in patients suffering from carcinoma of the esophagus. "
|1.||squamous cell carcinoma-related antigen
|2.||Biological Tumor Markers (Tumor Markers)
|3.||Keratin-19 (Keratin 19)
|4.||pro-gastrin-releasing peptide (31-98)
|5.||Tissue Polypeptide Antigen
|9.||Biological Markers (Surrogate Marker)
|10.||Phosphopyruvate Hydratase (Enolase)
|1.||Drug Therapy (Chemotherapy)